Q4 2024 Management View CEO Stephan Tanda highlighted that Aptar achieved 2% core sales growth in Q4 2024 and delivered adjusted EPS of $1.52, exceeding the top end of guidance due to ...

(NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter results due to solid operational performance driven by top ...

Aptar Beauty's Nomad Refill allows consumers to refill their favorite scent in under five seconds, while offering ...

LTR Pharma and Aptar Pharma have entered into a co-development agreement for Spontan The primary goal is commercialisation of ...

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using spot rates as of December 31, 2024 for all applicable ...

Hard on the heels of the official launch of its digital disease management platform, Aptar Pharma has secured a partnership with Italian drugmaker Chiesi to deploy it in support of patients. The ...

Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science ...

Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science ...

Shares of AptarGroup, Inc. (NYSE:ATR – Get Free Report) saw unusually-high trading volume on Friday following a better than expected earnings announcement. Approximately 323,073 shares traded hands ...

Vanessa Kanu Kanu; Executive Vice President and Chief Financial Officer; Aptargroup Inc Ladies and gentlemen, thank you for standing by. Welcome to Aptar 2024 fourth quarter and annual results ...